Sandoz Group AGSDZ.SW
What Sandoz Group AG does.
Sandoz Group AG develops, manufactures, and markets generic and biosimilars worldwide. The company covers therapeutic areas, including cardiovascular, central nervous system, oncology, infectious diseases, pain and respiratory, supportive care, rare diseases, diabetes, immunology, endocrinology, neurology, osteoporosis, nephrology, hematology, and ophthalmology. It also provides a portfolio of active pharmaceutical ingredients and finished dosage forms. The company has a strategic collaboration with Shanghai Henlius Biotech, Inc. to broaden patient access to biosimilar medicines. Sandoz Group AG was founded in 1886 and is headquartered in Basel, Switzerland.
Revenue and profit, by fiscal year.
| Fiscal year | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $9.3B | $10.0B | $10.4B | $11.2B |
| Net income | $848.0M | $77.0M | $0 | $914.0M |
| Free cash flow | $796.0M | -$263.0M | $60.0M | $810.0M |
More on SDZ.SW.
- Sandoz Group AG summary
- Sandoz Group AG financial statements
- Sandoz Group AG key metrics
- Sandoz Group AG health scores
- Sandoz Group AG valuation
- Sandoz Group AG dividends
- Sandoz Group AG peers
- Sandoz Group AG annual reports
Figures from Sandoz Group AG's annual reports (ESEF, via filings.xbrl.org) and Yahoo Finance, standardised automatically; prices are end-of-day closes. Not financial advice.